The transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts is the key process in liver fibrosis. By using a comprehensive series of in vitro and in vivo mouse and human models and performing exhaustive functional experiments, the authors showed that combined inhibition of the epigenetic modifiers G9a and DNMT1 is able to induce metabolic reprogramming, repressing fibrosis. This therapeutic strategy could help limit liver fibrosis, and as consequence, cirrhosis and liver cancer.

Marina Barcena-Varela et at, – BMJ Journal, 23 April 2020